

16 December 2010

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000



cyclomedica
molecular imaging
technegas

Cyclopharm Limited
ABN 74 116 931 250
Suite 630 Level 6
1 Queens Road
Melbourne Victoria 3004
Australia
T 61 3 9867 2811
F 61 3 9820 5957
www.cyclopharm.com

Cyclopet sells commercial FDG doses

On 3 December 2010 Cyclopharm Limited (ASX: CYC) announced to its Shareholders that the wholly owned subsidiary Cyclopet Pty Limited (Cyclopet) received Good Manufacturing Process (GMP) license approval from the Australian Therapeutic Goods Administration (TGA) for the cyclotron production and research facility located at Macquarie University Hospital (MUH).

Cyclopharm is pleased to advise Shareholders that the first commercial doses of the radiopharmaceutical compound F18 Flurodeoxyglucose (FDG) for use in Positron Emission Tomography (PET) scanning have been sold. PET is the fastest growing nuclear medicine diagnostic imaging modality in the world. PET is clinically proven to better identify the location and extent of certain active cancer cells in the body as well as many neurodegenerative diseases.

Macquarie Medical Imaging (MMI) purchased the first commercial doses of FDG. MMI, Cyclopharm's medical imaging joint venture with Alfred Health Solutions provides access state of the art imaging facilities including 3T MRI, CT, X-ray, Ultrasound and PET scanning for the new hospital and neighbouring suburbs.

The first patient injected with our product confirmed the presence and location of Squamous Cell Carcinoma (SCC). SCC is a form of cancer of the carcinoma type that may occur in many different organs, including the skin, lips, mouth, esophagus, urinary bladder, prostate, lungs, vagina, and cervix. 115,000 Australians will be diagnosed with cancer this year. This figure represents a 10% increase since 2006. Cyclopet's products and research will play a major role in early diagnosis and therapeutic management of these cancer patients.

Cyclopet will provide radiopharmaceuticals for both private and public PET departments including to its first customer MMI located co-located at MUH.

James McBrayer
Managing Director

Contact details:

Mr James McBrayer
Managing Director
Cyclopharm Limited
T: +61 2 9541 0411

Background

Cyclopharm Limited

Cyclopharm is a radiopharmaceutical company servicing the medical global medical community. The Company's mission is to enable nuclear medicine and other clinicians with the ability to improve patient care outcomes.

Cyclopharm achieves this objective through the provision of radiopharmaceutical products, Technegas (for lung imaging) and Molecular Imaging / PET radiopharmaceuticals (used in cancer, brain and cardiac imaging). Our customers are nuclear medicine departments located within hospitals and clinics.

Technegas

The Technegas technology is a structured ultra-fine dispersion of radioactive labeled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnace for a few seconds at around 2,500°C. The resultant gaseous substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for the superior diagnosis of pulmonary emboli (blood clots in the lungs).

Positron Emission Tomography (PET)

PET radiopharmaceuticals target specific tissues / organs, concentrate there, and the attached radioisotope emits radiation, which is then detected by a PET or PET / CT gamma (collectively PET camera). These imaging modalities help physicians improve their ability to detect and determine the location, extent and stage of cancer, neurological disorders and cardiac disease. By improving diagnosis, PET scans aid physicians in selecting better courses of treatment, as well as assessing whether treatment is effective or should be changed.

Macquarie University Hospital and the Macquarie University School of Advanced Medicine

Macquarie University Hospital is a major medical precinct within the Macquarie University Research Park to complement the Allied Health teaching services offered by Macquarie University.

The Macquarie University Hospital is a state of the art facility that delivers health education and research on site.

Macquarie Medical Imaging

Cyclopharm formed a joint venture with Alfred Health Solutions to provide all imaging services on-site at the hospital. The new venture named Macquarie Medical Imaging ("MMI") represents a rare strategic opportunity to provide a fully aligned and integrated diagnostic, therapeutic and research platform. MMI offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients.

The combination of state of the art imaging equipment, a GE cyclotron located on the grounds of MUH, leading surgeons, clinicians and academics will ensure that MMI will become the leading centre of imaging excellence.